AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05412381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasma (PRP) injection
Description: We aim to evaluate early catabolic and inflammatory changes in knee joints in patients receiving PRP injections following ACL injury, as these patients are at higher risk of developing PTOA. We also aim to establish correlations between markers of biologic activity of PRP and clinical outcomes (including both patient-reported outcomes and clinical functional outcomes), with emphasis on cellular and molecular inflammatory parameters modulated by PRP.
Study NCT05412381 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline injection
Description: Patients randomized into the control arm will receive the placebo or saline injection
Study NCT06563596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Bruton tyrosine kinase inhibitor, 80 mg immediate-release capsule, taken orally per protocol.
Study NCT04717609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: preoperatively the participant will receive an injection ar the surgical site of 5 milliliters (mL) of 0.5% ropivacaine
Study NCT06563596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Chimeric anti-CD20 monoclonal antibody, 10 or 50 mL single-use vials, via intravenous infusion per institutional standard.
Study NCT06563596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody, 5 or 60 mg/mL vials, via subcutaneous (under the skin) injection per protocol.
Study NCT06646523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed bodyweight resistance training
Description: The participants of the experimental group (high-speed bodyweight resistance training) will receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The experimental intervention will be performed at maximum speed. During the initial home visit, the speed at which the participant can perform one set of each exercise at maximum speed will be timed. Speed-based progression will be determined every four weeks by increasing the number of repetitions in each set of exercises performed during subsequent home visits.
Study NCT06646523 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group (Bodyweight intervention, usual speed)
Description: The participants of the control group (Bodyweight intervention, usual speed) will also receive a home-based intervention that will include 5 minutes of warm-up (free active movements of trunk and lower limbs), followed by 50 min of exercises more targeted to the lower limb muscles, and by 5 minutes of cool-down (lower limb muscle stretching and relaxation breathing exercise).~The control intervention will be performed at the usual speed. The same procedures that will be carried out to determine the maximum speed in the experimental group will be used to determine the usual speed in the control group. There will be no progression in the speed of performing the exercises. However, participants in the control group will also receive a home visit from the main researcher every four weeks to avoid bias related to the amount of attention given to participants in the experimental group.
Study NCT05731609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Intensive Personal Training
Description: Personalized power training program focused on participant goals.
Study NCT04649242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant/BHV3000
Description: BHV3000 (rimegepant) 75 mg or 50 mg ODT
Study NCT04649242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching 75 mg or 50 mg ODT placebo
Study NCT05949580 — intervention group
Intervention type: DEVICE
Intervention: MS Care Platform (icobrain ms and icompanion ms)
Description: The MS care management platform consists of the following components:~1. icobrain ms which is a a cloud-based solution to quantify brain volume and brain abnormalities and changes thereof on MRI scans;~2. icompanion ms which consists of free participant mobile application (app) and a web portal for HCPs.~The information collected in the icompanion ms patient app and icobrain ms is then brought together in the icompanion ms HCP web portal which allows a comprehensive overview of disease data for every single participant.
Study NCT04086329 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nanosensor
Description: The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue.
Study NCT06224283 — intervention group
Intervention type: PROCEDURE
Intervention: Cryoablation
Description: Cryoablation, a technique used in interventional radiology, involves repeated cycles of freezing, leading to cell death. Recent studies showed that percutaneous image-guided cryoablation appears to be safe and effective for local control for patients with extra-abdominal desmoid tumors
Study NCT06495723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIS1
Description: The study intervention (LIS1) is a glyco-humanized polyclonal antibody drug which is formulated for IV administration.
Study NCT06227806 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial Tubercle Transfer
Description: Patients will receive the TTT surgery followed by a home exercise program.
Study NCT06227806 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Patients will receive an extensive home exercise program.
Study NCT04712539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Given PO
Study NCT04712539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Given PO
Study NCT06284746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirolizumab+SOX/XELOX
Description: Tirolizumab combined with chemotherapy(SOX/XELOX) regimen. The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Study NCT06284746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX/XELOX
Description: Simple chemotherapy regimen (SOX/XELOX regimen). The SOX regimen consists of the drugs Tegilol (S-1) and Oxaliplatin. The XELOX regimen consists of the drugs oxaliplatin and capecitabine.
Study NCT04712539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Given PO
Study NCT05392296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power ball
Description: experimental group getting the power ball training with conventional treatment.
Study NCT05392296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isometric hand grip strengthening exercises
Description: conventional treatment (isometric hand grip training exercises)
Study NCT05226767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NLC-V
Description: NLC-V
Study NCT05226767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NLC-V
Description: NLC-V
Study NCT03981185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated theta burst treatment
Description: All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator.
Study NCT06231030 — intervention group
Intervention type: OTHER
Intervention: Validity, Reliability and Adaptation
Description: Expanded Disability Status Scale (EDSS) will be applied by a neurologist to determine the disability level of the individuals included in the study. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be administered by an expert physiotherapist. The questionnaires and scales to be used in the study will be administered by face-to-face interview method twice in total with two weeks intervals. In addition to the USE-MS scale, the GSE questionnaire, MuSiQoL and NFI-MS will be applied. The questionnaires and scales to be used in the study will be administered by face-to-face interview method 2 times in total with a 2-week interval.
Study NCT04838041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib 40 MG
Description: 40 mg by mouth (PO) when used with imatinib.
Study NCT04838041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib 40 MG Twice Daily
Description: 40 mg twice daily when used with nilotinib.
Study NCT04838041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib 80 MG daily
Description: 80 mg daily when used with dasatinib.
Study NCT04838041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Maximum dose of 400 mg PO once daily.
Study NCT04838041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Maximum dose of 300 mg twice daily.
Study NCT04838041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Maximum dose of 100 mg PO once daily.
Study NCT05369780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Collagen Peptide
Description: Dietary Hydrolized Collagen Peptide sourced from bovine
Study NCT05369780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hydrolyzed Collagen Peptide
Description: Dietary Hydrolized Collagen Peptide sourced from bovine
Study NCT03549819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Oil Capsules
Description: 200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
Study NCT03549819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Lecithin Oil in Capsule
Description: Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
Study NCT04078074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maxillary OSS
Description: Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
Study NCT04078074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular OSS
Description: Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
Study NCT04078074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified farrar splint
Description: Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
Study NCT06174116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Subject will take lumateperone (Caplyta) for 12 weeks, in addition to their regular medications.
Study NCT06174116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will take placebo for 12 weeks, in addition to their regular medications.
Study NCT06237673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: CT-directed clinical management strategy
Study NCT06237673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: invasive coronary angiography (ICA)
Description: Standard clinical management directed by conventional invasive coronary angiography (ICA).
Study NCT06508788 — intervention group
Intervention type: DEVICE
Intervention: CO2 laser
Description: Application of CO2 vulvo-vaginal laser according to standard therapy and moisturizing gels
Study NCT06300892 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: samples from the incision site and GI tract collected
Study NCT04618406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO VAC
Description: PICO14 device from Smith and Nephew - Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager-sized) suction device/canister and provides a negative pressure of -80 mmHg for 14 days.
Study NCT04618406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Sterile surgical silicone foam dressing and soft dressing applied immediately postoperative and removed after 12 days
Study NCT04602819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoSure 755nm picosecond alexandrite laser with diffractive lens
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography and other noninvasive methods.
Study NCT04602819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ApolloVue® S100 Image System
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with optical coherence tomography.
Study NCT04602819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutometer® dual MPA 580
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the Cutometer® dual MPA 580.
Study NCT04602819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISIA®
Description: Understand the role of 755nm picosecond alexandrite laser with diffractive lens of reversal of photodamage and improving the melasma by evaluation with the VISIA®.
Study NCT04888728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWN12088
Description: Prolyl-tRNA synthetase (PRS) inhibitor
Study NCT04888728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol
Study NCT04888728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine
Study NCT05691712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.
Study NCT05691712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC as add-on to the pre-trial background medication.
Study NCT05334368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depemokimab
Description: Depemokimab will be administered.
Study NCT05334368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered.
Study NCT05103384 — intervention group
Intervention type: OTHER
Intervention: Virtual Reality Environment
Description: Participants complete various tasks in a virtual home and grocery store environment.
Study NCT05392296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric hand grip strengthening exercises
Description: conventional treatment (isometric hand grip training exercises)
Study NCT05763797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Interview
Description: Group 1, participant will be in a supportive care program with other Black cancer patients in which you will practice meditation.~Group 2, participate will be in a supportive care program with other Black cancer patients that focuses on coping with cancer.~Participants will be asked to participate weekly sessions for 4 weeks (that is a total of 4 sessions) and each session will last about 60 minutes. Both groups will be delivered via Zoom (a web-based videoconferencing service) and led by a master's-level interventionist.
Study NCT06387602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Take an icepack and wrap it in a moisture-absorbing towel. The temperature of the icepack should be between 1˚ to 10˚. Any temperature below 0˚ can damage the skin. The icepack will be on strained adductors for 5-7 minutes. Patients will be advised to do cryotherapy at home for 24-42 hours after every 2 hours.
Study NCT06387602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening of adductors
Description: Both groups will perform the following strengthening of adductors which includes adductor isometrics, Side-lying adductor strengthening, and Adductor resistance with a stepper and will be done 10 repetitions, 3 times a week.~After the performance of the Adductor strengthening protocol, Group A will be given the Active release technique while Group B will be given post-isometric relaxation by the therapist.
Study NCT06387602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active release technique
Description: Step 1: Place the body in a position (Dorsiflex ankle, flex the knee, extend the hip, flex the spine) so that the nerve is moved proximally. In this position, the nerve is relaxed on the distal side of the entrapment site and the nerve is tractioned on the proximal side.~Step 2: Place contact between the distal Gracilis and the Sartorius and push the muscle proximally. The contact should not compress the nerve.~Step 3: Move each joint so that the nerve moves distally past the muscle. The new position (Plantarflex and evert the ankle, extend the knee, flex the hip, extend the spine) will be achieved.~Step 4: Move the contact to the proximal side of the muscles and push the muscle distally.~Step 5: Move the nerve proximally again by pushing the muscle distally. This brings the position of the patient back to Step 1.~Contact will be held for a short time 5-20 seconds with repetitions 3-5 times to the injury site and 2 sessions per week.
Study NCT06387602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation
Description: Step 1: Position the patient's limb at a point with the highest resistance felt during abduction.~Step 2: The patient is asked to bring the leg back into adduction using only 20% of strength against firm resistance given by the therapist.~Step 3: The patient will contract the agonist (the muscle that needs to be released) while holding an inhaled breath. Contraction should be held between 7-10 seconds without any jerking, bouncing, or wobbling.~Step 4: The patient is asked to release their effort slowly and completely. As the patient relaxes, the limb is guided into a new resistance barrier where a bind is felt again.~Step 5: After PIR, a 10-20-second latency period exists and the muscle can be stretched more easily.~Contract adductor muscle for 7-10 seconds and relax the same for 7-10 seconds with repetitions 7 times and 2 sessions per week.
Study NCT05530187 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Patient-reported Outcomes-based Model of Care
Description: Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).
Study NCT05912348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Physical Activity and Added Carbohydrate Group
Description: Young men and women will transition into a low physically active lifestyle for 10 days and consume added sugar-sweetened beverages. The intervention group will be compared to two control groups and one experimental group. One of the control groups will undergo a low physical activity intervention.